1. Home
  2. NSSC vs GLPG Comparison

NSSC vs GLPG Comparison

Compare NSSC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NAPCO Security Technologies Inc.

NSSC

NAPCO Security Technologies Inc.

HOLD

Current Price

$36.36

Market Cap

1.6B

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$27.75

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSSC
GLPG
Founded
1969
1999
Country
United States
Belgium
Employees
N/A
452
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.9B
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
NSSC
GLPG
Price
$36.36
$27.75
Analyst Decision
Strong Buy
Buy
Analyst Count
6
2
Target Price
$48.17
$36.50
AVG Volume (30 Days)
376.0K
159.1K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
1.33%
N/A
EPS Growth
N/A
N/A
EPS
0.70
N/A
Revenue
$181,621,000.00
N/A
Revenue This Year
$13.63
N/A
Revenue Next Year
$10.05
N/A
P/E Ratio
$52.99
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.44
$26.62
52 Week High
$47.61
$37.78

Technical Indicators

Market Signals
Indicator
NSSC
GLPG
Relative Strength Index (RSI) 33.99 36.53
Support Level $35.89 N/A
Resistance Level $44.43 $34.04
Average True Range (ATR) 1.33 0.56
MACD -0.20 0.08
Stochastic Oscillator 15.15 25.33

Price Performance

Historical Comparison
NSSC
GLPG

About NSSC NAPCO Security Technologies Inc.

NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: